Replicon RNA COVID-19 Vaccine
COVID-19 Prevention
Preclinical/DevelopmentPartnership Development with VLPT Japan
Key Facts
Indication
COVID-19 Prevention
Phase
Preclinical/Development
Status
Partnership Development with VLPT Japan
Company
About BIKEN Group
Japanese specialty vaccine organization developing and manufacturing traditional and novel RNA-based vaccines for infectious diseases.
View full company profileTherapeutic Areas
Other COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Intranasal COVID Vaccine | Virpax Pharmaceuticals | Research |
| COVID-19 Vaccine Trials | DM Clinical Research | Not Specified |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| COVAXIN | Bharat Biotech | Commercial |
| iNCOVACC | Bharat Biotech | Commercial |
| IRT Platform (e.g., COVID-19) | Biological Mimetics | Research/Pre-clinical |
| Convidecia Air® (XBB.1.5 Variant) | CanSino Biologics | Approved |
| COVID-19 Vaccine | Recbio Technology | Not specified |
| COMIRNATY® (BNT162b2) | Fosun Pharma | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| COVID-19 mRNA Vaccine (SYS6006) | CSPC Innovation Pharmaceutical | Marketed |